Application of miRNA-181d-5p mimetics targeting liver in treatment of non-alcoholic fatty liver disease

By injecting miRNA-181d-5p mimics targeting the liver, the lack of drugs for NAFLD treatment was addressed, resulting in effective improvement of liver tissue and reduction of related pathological indicators.

CN119020358APending Publication Date: 2024-11-26RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410949535.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

There are currently no effective drugs for treating non-alcoholic fatty liver disease (NAFLD), and the application of miRNA in NAFLD has not been fully developed.

Method used

A miRNA-181d-5p mimic targeting the liver was developed. The liver tissue was overexpressed by subcutaneous injection of miRNA-181d-5p. GalNAc or liposomes were used as delivery vectors. The structure was modified with nucleotides to enhance stability and reduce NAFLD-related indicators.

Benefits of technology

It significantly reduced liver weight and triglyceride content in NAFLD mice, decreased serum alanine aminotransferase and aspartate aminotransferase levels, and reduced liver collagen content and lipid accumulation, providing a new treatment approach for NAFLD.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020358A_ABST
    Figure CN119020358A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biomedical engineering, and provides an application of a miRNA-181d-5p analogue in preparation of a medicine for treating a non-alcoholic fatty liver disease. The invention provides miRNA-181d-5p analogues, application of the miRNA-181d-5p analogues to treatment of indications of non-alcoholic fatty liver diseases and a corresponding pharmaceutical composition of the miRNA-181d-5p analogues. Experiments prove that by injecting the miRNA-181d-5p analogue, miRNA-181d-5p can be overexpressed in liver tissues, meanwhile, the weight of the liver of an NAFLD mouse, the content of triglyceride in the liver and the level of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase in serum can be reduced, and the collagen content and lipid accumulation in the liver tissues of the NAFLD mouse can be reduced. Therefore, the invention provides a new way and exploration direction for the treatment of the non-alcoholic fatty liver disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and relates to the use of miRNA-181d-5p as a target in the preparation of a drug for treating non-alcoholic fatty liver disease, and specifically relates to a miRNA-181d-5p mimic, the use of the mimic in a drug for treating non-alcoholic fatty liver disease, and also relates to a pharmaceutical composition containing the mimic. Background Art

[0002] Nonalcoholic fatty liver disease (NAFLD) has become an important cause of chronic liver disease worldwide. [1-4] NAFLD is defined as the presence of more than 5% steatosis in the liver in the absence of other causative factors for fatty liver disease, such as substance abuse, autoimmune disease, or viral hepatitis. [1,2,5,6] NAFLD is a benign condition but may progress to more serious diseases such as nonalcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis, and ultimately hepatocellular carcinoma (HCC) and cardiovascular disease. [3,7-9] The overall prevalence of NAFLD in the Asian population is estimated to be approximately 29.6%, and its prevalence has steadily increased over time, from 25.3% during the period 1999 to 2005, to 28.5% during the period 2006 to 2011, and to 33.9% during the period 2012 to 2017.

[10] Asia as a whole has experienced rapid industrialization and socioeconomic growth, leading to the prevalence of sedentary lifestyles and high-calorie diets. [11,12] , which may be one of the reasons for the increasing prevalence of NAFLD. However, there is a severe shortage of drugs for the treatment of NAFLD, and there is only one drug on the market so far.

[0003] MicroRNA (miRNA) is a small non-coding RNA composed of 18-25 nucleotides that can alter gene expression by interfering with transcription. [9,13] miRNAs are key epigenetic factors in development [14,15] In NAFLD, previous studies have observed that dysregulated miRNA expression is involved in regulating pathological processes such as lipid metabolism, inflammatory activation, fibrosis, oxidative stress, and cell apoptosis, suggesting that miRNA plays a potentially important role in the occurrence and progression of NAFLD. [9,16] .

[0004] miRNA mimics are double-stranded RNA molecules that can upregulate miRNA levels by transfecting cells. Compared with the original miRNA, chemically modified miRNA mimics are more stable and less prone to degradation, and have broad application prospects in the treatment of cancer, cardiovascular disease, hepatitis and other diseases. Summary of the invention

[0005] The present invention is based on the above problems. The inventors found in their previous studies that miRNA-181d-5p has potential therapeutic value in non-alcoholic fatty liver disease. Related results confirm that overexpression of miRNA-181d-5p in liver tissue can effectively improve the pathological changes of NAFLD. Among them, the sequence of mouse miRNA-181d-5p is as follows:

[0006] AACAUUCAUUGUUGUCGGUGGGU (SEQ ID NO. 1).

[0007] On this basis, a liver-targeted miRNA-181d-5p mimic was developed and experimentally verified. The relevant results confirmed that subcutaneous injection of the miRNA-181d-5p mimic can cause liver tissue to overexpress miRNA-181d-5p and effectively improve the pathological changes of NAFLD.

[0008] The specific technical solutions of the present invention are as follows:

[0009] In a first aspect of the present invention, there is provided a miRNA-181d-5p mimic targeting the liver, which is formed by two modified complementary RNA chains and modified with a delivery carrier structure. The structures of the two modified RNA chains are as follows:

[0010] A~a~CAUUCAUUGUUgUcGGUGG~G~U(SEQ ID NO.2)

[0011] A~C~CCACcGacaACAAUGAAUGUU (SEQ ID NO. 3).

[0012] Capital letters represent that the second hydroxyl group of the ribose of the nucleotide is replaced by a methoxy group, lowercase letters represent that the second hydroxyl group of the ribose of the nucleotide is replaced by a fluorine atom, and ~ represents a phosphorothioate bond.

[0013] The transport carrier structure is selected from GalNAc or liposome, preferably a GalNAc modified structure, the structure is as follows:

[0014]

[0015] The preferred structural form of the liver-targeting miRNA-181d-5p mimics of the present invention is as follows:

[0016] A~a~CAUUCAUUGUUgUcGGUGG~G~U

[0017] A~C~CCACcGacaACAAUGAAUGUU-GalNAc

[0018] The above modifications can stabilize the oligonucleotide, making the miRNA-181d-5p mimics less susceptible to degradation by RNases in vivo and in vitro.

[0019] This modification is used to achieve in vivo targeting of hepatocytes. Through subcutaneous injection, we found that the miRNA-181d-5p mimic can cause liver tissue to overexpress miRNA-181d-5p, reduce the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the blood of NAFLD mice, reduce the content of triglyceride (TG) in liver tissue, and reduce the content of collagen in the liver.

[0020] In a second aspect, the present invention provides use of the miRNA-181d-5p mimics in the preparation of non-alcoholic fatty liver disease drugs.

[0021] The third aspect of the present invention provides a pharmaceutical composition for treating non-alcoholic fatty liver disease, comprising an active ingredient and a pharmaceutically acceptable excipient, wherein the active ingredient is the miRNA-181d-5p mimic described above.

[0022] In terms of drug form, the drug or drug composition is selected from the group consisting of drugs or drugs that are administered by the following modes: oral administration, injection, transdermal administration, etc.

[0023] When the composition of the present invention is administered to animals including humans, the dosage varies depending on the patient's age and weight, disease characteristics and severity, and administration route. The results of animal experiments and various circumstances can be referred to, and the total dosage cannot exceed a certain range.

[0024] Furthermore, the pharmaceutical composition of the present invention can be used in combination with other pharmaceutical compositions for treating non-alcoholic fatty liver disease.

[0025] Beneficial protection and effects of the present invention:

[0026] The present invention provides the use of miRNA-181d-5p analogs in the preparation of non-alcoholic fatty liver disease drugs. Experiments have confirmed that the injection of miRNA-181d-5p analogs can cause liver tissue to overexpress miRNA-181d-5p, and can also reduce the liver weight of NAFLD mice, the triglyceride content in the liver, and the levels of alanine aminotransferase and aspartate aminotransferase in serum, and reduce the collagen content and lipid accumulation in the liver tissue of NAFLD mice. Therefore, the present invention provides a new approach and exploration direction for the treatment of non-alcoholic fatty liver disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 It was shown that miRNA-181d-5p analogs promoted the expression of miRNA-181d-5p in the liver tissue of NAFLD mice.

[0028] Figure 2 Shown are the effects of miRNA-181d-5p analogs on liver weight.

[0029] Figure 3 The effects of miRNA-181d-5p analogs on triglyceride (TG) in the liver and ALT and AST levels in the serum of NAFLD mice were shown.

[0030] Figure 4 The effects of miRNA-181d-5p on liver collagen content and fatty infiltration in NAFLD mice are shown. DETAILED DESCRIPTION

[0031] The present invention is further described below with examples, but should not be construed as limiting the present invention. The examples do not include a detailed description of conventional methods, which are well known to those skilled in the art and are described in many publications.

[0032] Unless otherwise specified, percentages and parts of the present invention are calculated by volume; unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the present invention, and the preferred implementation methods and materials described in the specific implementation methods are for demonstration purposes only.

[0033] 1. Reagents

[0034] Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) detection kits were purchased from Sewell Biotechnology, isoflurane was purchased from Runan Beite China, miRNA reverse transcription kit and miRNA amplification kit were purchased from Ruibo Biotechnology, and triglyceride (TG) content detection kit was purchased from Prilai Biotechnology.

[0035] 2. miRNA-181d-5p analogs promote miRNA-181d-5p expression

[0036] After approval by the Animal Ethics Committee, the prepared miRNA-181d-5p mimics or negative control mimic Cel-miRNA-239b were aspirated with an insulin needle and injected subcutaneously into 8-week-old wild-type C57BL / 6J mice as the experimental group and the control group, respectively. After 3 days, the expression of miRNA-181d-5p in the liver tissue of mice was detected by real-time fluorescence quantitative PCR instrument. Figure 1 As shown, compared with the control group, subcutaneous injection of miRNA-181d-5p mimics could significantly promote the overexpression of miRNA-181d-5p in liver tissue.

[0037] 3. Mouse liver weight and serological tests

[0038] After 10 weeks of feeding with high-fat, high-cholesterol, and high-fructose feed, the above-mentioned miRNA-181d-5p mimics or negative control mimics were subcutaneously injected (10 mg / kg) once a week. After continuing to feed for 8 weeks on the above basis, the samples were collected. Specifically, the mice were placed on an electronic balance to weigh the weight of the mice and then placed in an anesthesia tank. After the anesthesia was stable, the eyeball was removed to obtain the peripheral blood of the mice. After the blood coagulated, the serum was precipitated and the serum was retained for serological testing. The mice were fixed on the operating board, the abdominal cavity of the mice was cut open with sterilized scissors, the mouse liver was cut off, and the weight of the mouse liver was weighed on a micro electronic balance.

[0039] The results are as follows Figure 2 As shown, injection of miRNA-181d-5p analogs significantly reduced the liver weight of NAFLD mice compared with control mice.

[0040] 4. Detection of ALT and AST in serum

[0041] The mice were placed in an anesthesia tank for anesthesia. After the anesthesia was stable, the mice were taken out and the eyeball was removed to obtain peripheral blood of the mice. After the blood was allowed to coagulate, it was centrifuged at a speed of 1000g for 2 minutes. After the centrifugation, the supernatant was obtained. If it was not tested immediately, it was stored in a deep low temperature refrigerator. If it was tested immediately, the serum was placed in a fully automatic animal blood biochemical analyzer for testing.

[0042] 5. Detection of triglyceride (TG) content in mouse liver tissue

[0043] Obtain liver tissues from two groups of mice and weigh them. Weigh about 50 mg of liver tissue and place it in a 1.5 ml centrifuge tube. Add 20 μl of lysate for every 1 mg of tissue. Use a tissue homogenizer to homogenize the tissue. Let it stand for 10 minutes after homogenization. Take an appropriate amount of supernatant and transfer it to a new 1.5 ml centrifuge tube. The remaining lysate is used for protein quantification by the BCA method. According to a 4:1 ratio, take 4 ml of reagent R1 and 1 ml of reagent R2 to form a detection working solution for immediate use. Use sample buffer to dilute the 4 mM glycerol standard to a concentration gradient of 1000, 500, 250, 125, 62.5, 31.25, 15.625, 7.8125, 0 μmol / L. Add 10 μl of sample and 190 μl of detection working solution to a 96-well plate and react at 37°C for 15 minutes. After obtaining the OD value, the sample concentration was calculated after calibration with a blank tube, and finally, the triglyceride content in the liver tissue was converted into micrograms per milligram of protein according to the aforementioned BCA protein quantification.

[0044] The results are as follows Figure 3 As shown, subcutaneous injection of miRNA-181d-5p mimic significantly reduced the triglyceride content in the liver of NAFLD mice ( Figure 3 A); Peripheral blood biochemical analysis showed that the ALT and AST levels in the serum of NAFLD mice were significantly reduced after subcutaneous injection of miRNA-181d-5p mimic ( Figure 3 B, 3C)

[0045] 6. H&E staining

[0046] The mouse liver tissue was obtained and placed in 4% paraformaldehyde, fixed at room temperature for 24 hours, and then routinely embedded in paraffin. The samples were placed on a paraffin slicer for slices with a thickness of 4-5um and then stained. The staining process was as follows: (1) Dewaxing: xylene (I) 15min → xylene (II) 15min → anhydrous ethanol 5min*2 times → 95% ethanol 5min*2 times → 80% ethanol 5min*2 times → 75% ethanol 5min*2 times → double distilled water washing several times; (2) Hematoxylin staining: after absorbing the water, hematoxylin staining for 5min, and rinsing with tap water; (3) Acidification: Differentiation in hydrochloric acid and alcohol for 60s; (4) Eosin staining: Soak in tap water for 15min, absorb the water and place in eosin solution for 3min; (5) Dehydration: after washing away the floating color with distilled water, 75% ethanol 40s → 95% ethanol 40s → anhydrous ethanol 40s in turn; (6) Transparentization and fixation: xylene (I) 2min → xylene (II) 2min → xylene (II) 2min → neutral resin sealing and fixation. After drying, the samples were photographed under an optical microscope.

[0047] 7. Sirius red staining

[0048] Obtain mouse liver tissue and place it in 4% paraformaldehyde, fix it at room temperature for 24 hours, and then embed it in conventional paraffin. The sample is placed on a paraffin slicer for sectioning, and the section thickness is 4-5um. The staining process is as follows: (1) Dewaxing: xylene (I) 15min→xylene (II) 15min→anhydrous ethanol 5min*2 times→95% ethanol 5min*2 times→80% ethanol 5min*2 times→75% ethanol 5min*2 times→double distilled water washing several times; (2) Use Sirius red staining solution to stain for 10-15 minutes, and rinse off the staining solution with running water. (3) Prepare iron hematoxylin staining solution, add it dropwise for staining for 5-10 minutes, and wash with running water for 10-20 seconds; (4) Dehydration: 75% ethanol for 40 seconds → 95% ethanol for 40 seconds → anhydrous ethanol for 40 seconds; (6) Transparentization and fixation: xylene (I) for 2 minutes → xylene (II) for 2 minutes → → xylene (II) for 2 minutes → neutral resin sealing and fixation. After drying, take pictures under an optical microscope.

[0049] The staining results are as follows Figure 4 As shown in the results, subcutaneous injection of miRNA-181d-5p mimic significantly reduced the collagen content in the liver of NAFLD mice ( Figure 4 A, 4B) and lipid accumulation ( Figure 4 C).

[0050] The references involved in the background technology of the present invention are as follows:

[0051] [1] YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes [J / OL]. Hepatology (Baltimore, Md.), 2016, 64(1): 73-84. DOI: 10.1002 / hep.28431.

[0052] [2]BYRNE CD,TARGHER G.NAFLD: a multisystem disease[J / OL].Journal ofHepatology,2015,62(1Suppl):S47-64.DOI:10.1016 / j.jhep.2014.12.012.

[0053] [3]TOMAH S,HAMDY O,ABUELMAGD M M,et al.Prevalence of and risk factors for non-alcoholic fatty liver disease(NAFLD)and fibrosis among young adults in Egypt[J / OL].BMJ open gastroenterology,2021,8(1):e000780.DOI:10.1136 / bmjgast-2021-000780.

[0054] [4]Recent research trends and updates on nonalcoholic fatty liver disease - PubMed[EB / OL].[2024-04-22].https: / / pubmed.ncbi.nlm.nih.gov / 30086613 / .

[0055] [5] A R, J,ESCRIBANO et al.miRNA Dysregulation in the Development of Non - Alcoholic Fatty Liver Disease and the Related Disorders Type 2 Diabetes Mellitus and Cardiovascular Disease[J / OL].Frontiers in Medicine,2020,7:527059.DOI:10.3389 / fmed.2020.527059.

[0056] [6]EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER(EASL),EUROPEANASSOCIATION FOR THE STUDY OF DIABETES(EASD),EUROPEAN ASSOCIATION FOR THESTUDY OF OBESITY(EASO).EASL-EASD-EASOClinical Practice Guidelines for themanagement of non-alcoholic fatty liver disease[J / OL].Journal of Hepatology,2016,64(6):1388-1402.DOI:10.1016 / j.jhep.2015.11.004.

[0057] [7]ALKHOURI N,FELDSTEIN A E.Noninvasive diagnosis of nonalcoholicfatty liver disease:Are we there yet?[J / OL].Metabolism:Clinical andExperimental,2016,65(8):1087-1095.DOI:10.1016 / j.metabol.2016.01.013.

[0058] [8]RINELLA M E,SANYAL A J.Management ofNAFLD:a stage-based approach[J / OL].Nature Reviews.Gastroenterology&Hepatology,2016,13(4):196-205.DOI:10.1038 / nrgastro.2016.3.

[0059] [9]FANG Z,DOU G,WANG L.MicroRNAs in the Pathogenesis ofNonalcoholicFatty Liver Disease[J / OL].International Journal of Biological Sciences,2021,17(7):1851-1863.DOI:10.7150 / ijbs.59588.

[0060]

[10] LI J, ZOU B, YEO Y H, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999 - 2019: a systematic review and meta-analysis[J / OL]. The Lancet. Gastroenterology & Hepatology, 2019, 4(5): 389 - 398. DOI: 10.1016 / S2468 - 1253(19)30039 - 1.

[0061]

[11] AL-DAYYAT H M, RAYYAN Y M, TAYYEM R F. Non-alcoholic fatty liver disease and associated dietary and lifestyle risk factors[J / OL]. Diabetes & Metabolic Syndrome, 2018, 12(4): 569 - 575. DOI: 10.1016 / j.dsx.2018.03.016.

[0062]

[12] Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention - PubMed[EB / OL].[2024 - 04 - 22].https: / / pubmed.ncbi.nlm.nih.gov / 28930295 / .

[0063]

[13] SZABO G, CSAK T. Role of MicroRNAs in NAFLD / NASH[J / OL]. Digestive Diseases and Sciences, 2016, 61(5): 1314 - 1324. DOI: 10.1007 / s10620 - 015 - 4002 - 4.

[0064]

[14] BAFFY G. MicroRNAs in Nonalcoholic Fatty Liver Disease[J / OL]. Journal of Clinical Medicine, 2015, 4(12): 1977 - 1988. DOI: 10.3390 / jcm4121953.

[0065]

[15] XIN S, ZHAN Q, CHEN

[0066]

[16] NEWMAN LA,USECKAITE Z,JOHNSON J,et al.Selective Isolation of Liver-Derived Extracellular Vesicles Redefines Performance of miRNA Biomarkers forNon-Alcoholic Fatty Liver Disease[J / OL].Biomedicines,2022,10(1):195.DOI:10.3390 / biomedicines10010195.

[0067] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.

Claims

1. A miRNA-181d-5p mimic, characterized in that It is formed by two modified complementary RNA chains and modified with a transport carrier structure, wherein the structures of the two modified RNA chains are as follows: A~a~CAUUCAUUGUUgUcGGUGG~G~U A~C~CCACcGacaACAAUGAAUGUU, Among them, capital letters represent that the second hydroxyl group of the ribose of the nucleotide is replaced by a methoxy group, lowercase letters represent that the second hydroxyl group of the ribose of the nucleotide is replaced by a fluorine atom, and ~ represents a phosphorothioate bond. The carrier structure is selected from liposome or GalNAc.

2. The miRNA-181d-5p mimic according to claim 1, characterized in that The structure of the miRNA-181d-5p mimic is as follows: A~a~CAUUCAUUGUUgUcGGUGG~G~U A~C~CCACcGacaACAAUGAAUGUU-GalNAc.

3. The miRNA-181d-5p mimic according to claim 1 or 2, characterized in that The structure of GalNAc is as follows:

4. Use of the miRNA-181d-5p mimetic according to any one of claims 1 to 3 in the preparation of a drug for non-alcoholic fatty liver disease.

5. A pharmaceutical composition for treating non-alcoholic fatty liver disease, characterized in that: The pharmaceutical composition comprises an active ingredient and a pharmaceutically acceptable excipient. Wherein, the active component is the miRNA-181d-5p mimic according to any one of claims 1 to 3.

6. The pharmaceutical composition for treating non-alcoholic fatty liver disease according to claim 5, characterized in that: The pharmaceutical composition is used in combination with other drugs for treating non-alcoholic fatty liver disease.